ArticleBMC bioinformatics2026
Srnc: semi-supervised learning for robust novel cell-type identification in single cell RNA sequencing data.
Article in BMC bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundSingle-cell RNA sequencing (scRNA-seq) enables the identification of cell types within complex biological systems, yet accurately classifying both known and novel cell types remains a significant challenge. Supervised learning methods perform well when all cell types are labeled in the training data, but struggle with unseen cell types, while rejection-based approaches can mitigate misclassification but fail to leverage unlabeled data for learning. Deep learning-based methods, such as MARS, offer promising solutions but often suffer from poor generalization to novel cell populations.
resultsWe propose Semi-supervised learning for Robust Novel Cell-type identification (SRNC), a novel semi-supervised framework that enhances classification accuracy while effectively identifying unknown cell types. By integrating self-supervised feature learning with semi-supervised classification, SRNC leverages both labeled and unlabeled data to improve generalization. Evaluated across six benchmark scRNA-seq datasets, SRNC consistently outperforms state-of-the-art methods, achieving higher ARI, F1-score, and precision than both the rejection-based approach and deep-learning-based MARS. Moreover, SRNC demonstrates robustness across datasets from different laboratories and excels in imbalanced classification scenarios, accurately identifying rare cell populations that other methods often misclassify.
conclusionsOur results demonstrate that SRNC is a powerful and adaptable tool for cell-type classification in scRNA-seq analysis. By leveraging semi-supervised learning, SRNC effectively identifies both known and novel cell types, surpassing competing methods in multiple performance metrics. Its ability to generalize across datasets and handle class imbalances makes it a valuable approach for discovering new cell types, advancing precision medicine, and improving our understanding of cellular heterogeneity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.